ArticleScientific reports2019
Effects of Chikungunya virus immunity on Mayaro virus disease and epidemic potential.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- The epidemiology of Mayaro virus in the Americas: A systematic review and key parameter estimates for outbreak modelling.PLoS neglected tropical diseases · 2021Pooled it
- Evaluation of Cross-Protective Responses against Mayaro Virus among Chikungunya Virus-Infected Patients from Paraguay.The American journal of tropical medicine and hygiene · 2026Article
- Investigating antibody cross-reactivity and transmission dynamics of alphaviruses and flaviviruses using a multiplex serological assay.Nature communications · 2026Article
- Rhesus macaques model human Mayaro virus disease and transmit to Aedes aegypti mosquitoes.PLoS neglected tropical diseases · 2025Article
- Vector-borne diseases and their role in COVID-19 dynamics and death rates: focus on India.Folia microbiologica · 2025Article
- Lack of pathogenic involvement of CCL4 and its receptor CCR5 in arthritogenic alphavirus disease.ImmunoHorizons · 2025Article
- Identification and Characterization of Antiviral Activity of Synthetic Compounds Against Mayaro Virus.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Neuropathogenesis of Old World Alphaviruses: Considerations for the Development of Medical Countermeasures.Viruses · 2025Review
- RT-RPA as a dual tool for detection and phylogenetic analysis of epidemic arthritogenic alphaviruses.Scientific reports · 2024Article
- Humoral and T-cell-mediated responses to an insect-specific flavivirus-based Zika virus vaccine candidate.PLoS pathogens · 2024Article
- Article
- Mayaro Virus: An Emerging Alphavirus in the Americas.Viruses · 2024Review
- Comparative pathogenesis of three Mayaro virus genotypes in the cynomolgus macaque.The Journal of general virology · 2024Article
- Mayaro virus pathogenesis and immunity in rhesus macaques.PLoS neglected tropical diseases · 2023Article
- Mouse Models of Mayaro Virus.Viruses · 2023Review
- The E2 glycoprotein holds key residues for Mayaro virus adaptation to the urban Aedes aegypti mosquito.PLoS pathogens · 2023Article
- Comparative Efficacy of Mayaro Virus-Like Particle Vaccines Produced in Insect or Mammalian Cells.Journal of virology · 2023Article
- Infection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein.PLoS neglected tropical diseases · 2023Article
- Expression of anti-chikungunya single-domain antibodies in transgenicFrontiers in microbiology · 2023Article
- A high-throughput screening assay to identify inhibitory antibodies targeting alphavirus release.Virology journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
Mayaro virus (MAYV) causes an acute febrile illness similar to that produced by chikungunya virus (CHIKV), an evolutionary relative in the Semliki Forest virus complex of alphaviruses. MAYV emergence is typically sporadic, but recent isolations and outbreaks indicate that the virus remains a public health concern. Given the close phylogenetic and antigenic relationship between CHIKV and MAYV, and widespread distribution of CHIKV, we hypothesized that prior CHIKV immunity may affect MAYV pathogenesis and/or influence its emergence potential. We pre-exposed immunocompetent C57BL/6 and immunocompromised A129 or IFNAR mice to wild-type CHIKV, two CHIKV vaccines, or a live-attenuated MAYV vaccine, and challenged with MAYV. We observed strong cross-protection against MAYV for mice pre-exposed to wild-type CHIKV, and moderately but significantly reduced cross-protection from CHIKV-vaccinated animals. Immunity to other alphavirus or flavivirus controls provided no protection against MAYV disease or viremia. Mechanistic studies suggested that neutralizing antibodies alone can mediate this protection, with T-cells having no significant effect on diminishing disease. Finally, human sera obtained from naturally acquired CHIKV infection cross-neutralized MAYV at high titers in vitro. Altogether, our data suggest that CHIKV infection can confer cross-protective effects against MAYV, and the resultant reduction in viremia may limit the emergence potential of MAYV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.